Soleus Capital Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001802630

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2024 · 91 positions · Total reported value $1.35B · Top-10 concentration 45.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 72.6% · 27 new · 36 cut · 27 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -6.9% · vs SPY -9.0% · Prev Value $2.90B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.4% · vs SPY -3.6% · Latest Value $2.81B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2024 13F filing, Soleus Capital Management, L.P. disclosed 91 equity positions with a combined reported value of $1.35B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2024 were XBI ($208.76M), UTHR ($59.67M), FOCL ($53.12M). By sector, the heaviest allocations are Health Care 69.0%, Materials 1.0%. Versus the prior quarter, allocation shifted toward Other (+6.2pp) and away from Consumer Staples (-0.5pp), Health Care (-5.7pp).

Versus the prior quarter, Soleus Capital Management, L.P. opened 27 new positions, trimmed 36 and fully exited 27, a turnover rate of 72.6% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q1 2024 were XBI ($208.76M), ONC ($23.16M), KROS ($18.11M).

Of the 27 positions fully exited versus the prior quarter, the largest were RYZB ($46.42M), ATRC ($14.00M), SNN ($12.83M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2024)

  • XBI SPDR SERIES TRUST · $208.76M
  • ONC BEONE MEDICINES LTD · $23.16M
  • KROS KEROS THERAPEUTICS INC · $18.11M
  • BIIB BIOGEN INC · $15.70M
  • ENGN ENGENE THERAPEUTICS INC · $13.56M
  • NARI INARI MED INC · $13.29M
  • ENTA ENANTA PHARMACEUTICALS INC · $10.14M
  • CGON CG ONCOLOGY INC · $9.56M

Fully Exited (vs previous quarter)

  • RYZB RAYZEBIO INC · prev qtr: $46.42M
  • ATRC ATRICURE INC · prev qtr: $14.00M
  • SNN SMITH & NEPHEW PLC · prev qtr: $12.83M
  • HARP HARPOON THERAPEUTICS INC · prev qtr: $9.33M
  • SIBN SI BONE INC · prev qtr: $7.17M
  • CVS CVS HEALTH CORP · prev qtr: $4.70M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $2.67M
  • HOLX HOLOGIC INC · prev qtr: $2.43M

Insider Transactions (Form 4)

Latest Soleus Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-11 Conversion Parabilis Medicines, Inc. 527,070 $9.48 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 125,000 $20.00 SEC filing
2026-06-11 Buy Parabilis Medicines, Inc. 375,000 $20.00 SEC filing

All insider transactions →

Fund Profile

Soleus Capital Management, L.P. is an SEC-registered 13F filer based in Greenwich, CT, United States. As of Q3 2026 it reported 97 US equity positions with a combined value of $2.81B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: GREENWICH, CT, United States
  • SEC registration: 801-118942 (status: Approved), registered 2020-06-25
  • Regulatory AUM (Form ADV): $3.66B as of 2026-04-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 12 private funds, of which 1 hedge funds

Portfolio Structure

  • 97 positions · $2.81B reported value (Q3 2026)
  • Top 10 holdings = 53.0% of reported value
  • Largest position: KRYS (KRYSTAL BIOTECH INC) at 13.5%
  • Average position size: $29.00M

Sector Tilt

  • Health Care 98.6%
  • Information Technology 0.0%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q3 2026: 27 new, 28 added, 36 reduced, 27 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 69.0%
Materials 1.0%
Other 30.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 2.20M $208.76M 15.49%
15.49%
New
2 259.75K $59.67M 4.43%
4.43%
Add
3 7.23M $53.12M 3.94%
3.94%
Hold
4 3.50M $51.94M 3.85%
3.85%
Add
5 3.49M $49.19M 3.65%
3.65%
Reduce
6 3.17M $48.19M 3.58%
3.58%
Add
7 1.73M $37.40M 2.77%
2.77%
Reduce
8 1.19M $34.85M 2.59%
2.59%
Reduce
9 2.43M $32.12M 2.38%
2.38%
Hold
10 3.59M $30.48M 2.26%
2.26%
Reduce
11 9.57M $27.19M 2.02%
2.02%
Add
12 3.11M $25.06M 1.86%
1.86%
Add
13 72.01K $24.97M 1.85%
1.85%
Reduce
14 800.82K $23.50M 1.74%
1.74%
Add
15 728.70K $23.49M 1.74%
1.74%
Add
16 533.51K $23.41M 1.74%
1.74%
Reduce
17 148.10K $23.16M 1.72%
1.72%
New
18 2.46M $20.09M 1.49%
1.49%
Add
19 85.70K $19.13M 1.42%
1.42%
Add
20 1.54M $18.18M 1.35%
1.35%
Add
21 273.60K $18.11M 1.34%
1.34%
New
22 1.35M $17.56M 1.30%
1.30%
Add
23 51.44K $17.16M 1.27%
1.27%
Reduce
24 1.11M $16.39M 1.22%
1.22%
Add
25 725.46K $16.07M 1.19%
1.19%
Add
26 361.63K $15.91M 1.18%
1.18%
Reduce
27 72.80K $15.70M 1.17%
1.17%
New
28 84.10K $14.96M 1.11%
1.11%
Add
29 207.75K $14.19M 1.05%
1.05%
Reduce
30 4.07M $13.98M 1.04%
1.04%
Hold
31 319.22K $13.68M 1.02%
1.02%
Reduce
32 9.24M $13.68M 1.01%
1.01%
Reduce
33 800.00K $13.56M 1.01%
1.01%
New
34 277.00K $13.29M 0.99%
0.99%
New
35 695.76K $10.87M 0.81%
0.81%
Add
36 1.35M $10.72M 0.80%
0.80%
Add
37 1.56M $10.64M 0.79%
0.79%
Add
38 150.00K $10.43M 0.77%
0.77%
Reduce
39 580.55K $10.14M 0.75%
0.75%
New
40 129.29K $9.71M 0.72%
0.72%
Reduce
41 7.29M $9.63M 0.71%
0.71%
Add
42 217.87K $9.56M 0.71%
0.71%
New
43 267.87K $9.36M 0.69%
0.69%
Add
44 401.90K $9.29M 0.69%
0.69%
Add
45 570.98K $9.28M 0.69%
0.69%
Add
46 195.58K $8.81M 0.65%
0.65%
Reduce
47 369.00K $8.78M 0.65%
0.65%
Reduce
48 2.62M $8.64M 0.64%
0.64%
Reduce
49 264.65K $8.55M 0.64%
0.64%
Reduce
50 4.80M $7.97M 0.59%
0.59%
Hold

FAQ

What did Soleus Capital Management, L.P. buy in 2024-Q1?

In its 2024-Q1 13F filing, Soleus Capital Management, L.P. reported 91 equity positions worth $1.35B in aggregate; its largest disclosed positions were XBI ($208.76M), UTHR ($59.67M), FOCL ($53.12M).

How large is Soleus Capital Management, L.P.'s portfolio?

Soleus Capital Management, L.P. reported $1.35B of long equity holdings across 91 positions as of 2024-Q1. Top-10 holdings account for 45.0% of reported value.

What is Soleus Capital Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/soleus-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →